Modern surgical and biological therapy of breast cancer

Czech version

Authors: Vít Weinberger ¹ ; Luboš Minář ¹ ; D. Brančíková ²
Authors‘ workplace: Gynekologicko-porodnická klinika FN a LF MU, Brno, přednosta prof. MUDr. P. Ventruba, DrSc., MBA ¹; Interní hematoonkologická klinika FN a LF MU, Brno, přednosta prof. MUDr. J. Mayer, CSc. ²
Published in: Ceska Gynekol 2012; 77(6): 513-520

Overview

Breast cancer is the most common cancer of women in the Czech Republic. According to data from the National Cancer Registry (NOR) in 2007, the incidence is 122.7 cases of breast cancer in 100 000 women per year. Czech Republic occupies in the incidence of women brest cancer 26^th place in the world and 17^th place in Europe. Annualy it has been diagnosed 6500 these tumors, 1700–1900 women die for him in the Czech Republic (data from 2007). The incidence show long-term upward trend (an increase of 32% in 2007 compared to 1995), while mortality has long been stabilized. In this favorable outcome ivolved the introduction of systematic screeningu mammography in women over 45 years of age, diagnosis of early stages of disease, effective adjutant therapy and treatment of metastatic disease. In an international comparison of mortality, the Czech Republic belongs to 71^th place in the world and the 27^th place in Europe. Malignant neoplasm of breast cancer often affects women of working age, nearly 43% of patients are younger than 60 years. Long-term increasing incidence and stable mortality lead to a further increase in prevalence, which in 2007 reached more than 55 000 women living with breast cancer or its history. The various modalities of treatment include surgery, radiotherapy, systemic chemotherapy, hormonal therapy and targeted biological therapy.

Fastest-growing issues in breast cancer management is the sentinel nodes and non-invasive breast cancers. This entity was newly assigned and represented by a lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS). DCIS as noninvasive cancer of the breast is generally 15–20% of breast cancers diagnosed and the number is growing.

Key words:
breast cancer, surgery therapy, biological therapy.

Sources

1. Webový portál – SVOD: epidemiologie zhoubných nádorů v České republice. http://www.svod.cz.

2. Pavlišta, D. Neinvazivní karcinomy prsu. Praha: Maxdorf, 2008.

3. Stankušová, H. Strategie moderní léčby karcinomu prsu. Moder Gynek Porod, 2004, 13, 3, s. 502–519.

4. Petráková, K., Růžičková, J., Fait, V. Léčební postupy u karcinomu prsu. Klin Okol, 2008, 21, 4, s. 131–140.

5. Fait, V., et al. Chirurgie karcinomu prsu v České republice. Klin Okol, 2009, 22, 6, s. 294–295.

6. Fait, V., Chrenko, V., Gatěk, J. Sentinelová biopsie u karcinomu prsu a neoadjuvantní chemoterapie. Klin Okol, 2005, 3, s. 77–79.

7. Strnad, P. Chirurgická léčba karcinomu prsu, Moder Gynek Porod, 2004, 13, 3, s. 520–527.

8. Halsted, WS. The result of radical operations for the cure of carcinoma of the breast. Ann Surg, 1907, 66.

9. Veronesi, U., et al. Breast conservation is a safe method in patients with small cancer of the breast. Long term-results of three randomized trials on 1993 patients. Eur J Cancer, 1995, 31A, p. 1574.

10. Fait, V., et al. Sentinelová biopsie a možnosti využití v současné onkochirurgii. Klin Okol, 2008, 21, 1, s. 5–19.

11. Pavlišta, D., Dudorkinova, D., Novotný, J. K problematice vyšetřeni sentinelovych lymfatickych uzlin u karcinomu prsu. Čes Gynek, 2005, 70, 3, s. 197–200.

12. Guliano, AE., et al. Sentinel lymphadenectomy in breast cancer.J Clin Oncol, 1997, 15, p. 2345.

13. Kubíčková K. Herceptin v léčbě karcinomu prsu. Moder Gynek Porod, 2004, 13, 3, p. 528–535.

14. Harris, M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol, 2004, 292.

15. „FDA begins process to remove breast cancer indication from Avastin label“ (Press release). FDA. 2010-12-16.

16. http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/ucm237172.htm. Retrieved 2010-12-17.

17. Vogel, CL., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20, p. 719.

18. Hudis, CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med, 2007, 357, 1, p. 39–51.

19. Romond, EH., Perez, EA., Bryant, J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005, 353, 16, p. 1673–1684.

20. Littlejohns, P. Trastuzumab for early breast cancer: evolution or revolution? Lancet Oncol, 2006, 7, 1, p. 22–23.

21. Kovtun, YV., Goldmacher, VS. Cell killing by antibody-drug conjugates. Cancer letters, 2007, 255, 2, p. 232–240.

22. Celldex Therapeutics Announces Initiation of Randomized Phase 2b Clinical Trial of CDX-011 In Advanced Breast Cancer. 22 Sept 2010. http://currentcancer.com/celldex-therapeutics-announces-initiation-of-randomized-phase-2b-clinical-trial-of-cdx-011-in-advanced-breast-cancer.html.

23. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial In Advanced Breast Cancer. 18 June 2009. http://www.medicalnewstoday.com/articles/154376.php.

24. Burris, HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist, 2004, 9. Suppl. 3, p. 10–15.

25. Nelson, MH., Dolder, CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother, 2006, 40, 2, p. 261–269.

26. http://www.parp-inhibitors.com/bsi201.html.

27. http://www.cancernetwork.com/display/article/10165/1514773 „Development of PARP Inhibitors: An Unfinished Story“ Jan 2010.

28. Olaparib, a PARP Inhibitor. Health and Life. http://healthlifeandstuff.com/2010/03/olaparib-a-parp-inhibitor.

29. Vasiliou, S., Castaner, R., Bolos, J. Olaparib. Drugs of the future, 2009, 34, 2, p. 101.

30. Lee, JB., Woo, OH., Park, KH., et al. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs, 2009, 16.

31. Gelmon, KJ. Resultsof a Phase II trial oftrastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic-breastcancer (MBC) who had progressedduringtrastuzumabtherapy. Proceedings from ASCO, 2008, Abs. TBC.

32. Baselga, JMD. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer, December 7, 2011 (10.1056/NEJMoa1109653).

33. ClinicalTrials.gov NCT00398567 A Phase 1/2 Study Of HKI-272 In Combination With Herceptin In Subjects With Advanced Breast Cancer.

34. Wilhelm, SM., Axmane, L., Newell, P., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics, 2008, 7, 10, p. 3129–3140.